Audit: QRS - D-Aspartic Acid to Improve Testosterone

Audit conducted on 19/09/2026 09:18 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every cell traced to ER: protocol cells to ER Therapeutic Protocol (lines 292, 300, 302, 304), time cells to ER lines 347, 157, 302, gates to ER lines 245-270, tiers to ER Expected Benefits / Potential Risks & Side Effects, all nine markers and cadence to ER lines 373-385.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“has never been tested, so no comparative data exist” (action_3_sub) carries ER line 304 verbatim; “near-silent on long-term safety” preserves ER line 418 “close to silent on long-term safety”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Avoid-list populations are carried at full strength into Contraindications; “nothing supports expecting a perceptible effect sooner” (time_1_sub) matches ER line 347 without softening.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Testosterone replacement / gonadotropins appears under Contraindications because ER line 249 labels it “Absolute contraindication”; no Benefit- or Risk-Modifying Factor content leaks into the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names anywhere in the QRS; only generic ingredient names (ubiquinol, zinc) that ER line 155 carries for the same fact.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced; the only sourcing language is the unattributed “in a trial of a product that also contained ubiquinol and zinc” from ER line 155.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Reserved, evidence-weighted register matches the ER throughout, including the negative framing of the efficacy signal.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Functional biomarker targets, dose ranges and cycle structure give actionable specificity without hype.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as what trials did and measured, not as instructions to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs directed at a reader; cadence is phrased as a testing schedule mirroring ER line 373.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised” or “should” constructions appear.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are expanded on first use in the Monitoring table (LH, SHBG, PSA, eGFR, ALT); “mirror-image amino acid” replaces “enantiomer”.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items and tier lines are bare noun phrases; sub-lines are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Nine-marker panel, two-draw baseline and functional ranges assume a proactive, testing-willing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Fasted morning draws a week apart and twelve-week repeat testing presume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a general-population “just try it” framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance and Benefits both surface the untrained-versus-trained split that determines whether this audience would expect any response.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route and dosing are stated clinically (“3 g daily”, “Morning, empty stomach” per ER line 300); no consumer-grade substitutes such as “pills” or “shots”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings byte-identical to [qrs_template]; remaining tier labels (“Low”/”Speculative” in Benefits, “Medium”/”Low”/”Speculative” in Risks) unmodified, with unused tiers removed per 12.5 / 13.5.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 named template variables present, plus the repeated marker_#* set expanded to marker_1..9 and qualitative_item# expanded to qualitative_item_1..6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three non-variable spans (website=”evidence_review”, website=”audit”, website=”full_review”) and the entire stylesheet block are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the unpopulated benefit/risk tiers carry explanatory ER prose and are governed by 12.5 / 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose and duration”, “Time of day”, “Single versus split dosing” and “Half-life” match the ER bold labels at lines 292, 300, 304 and 302 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names match the ER biomarker table verbatim, including parenthetical abbreviations (LH, SHBG, PSA, eGFR, ALT).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; tiering is carried by the CSS palette and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Single-line tier entries, nine compact table rows and short gate items keep the sheet within the one-page budget; no structural additions beyond the template.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at lines 2-14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3 and closing “—” at line 13, with the permitted caption line preceding it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: d_aspartic_acid_testosterone_2026-0919-0638_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0919-0907, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: git_user, git_issue and all other values are unquoted and untrimmed-free; only the colon-bearing duration is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “D-Aspartic Acid to Improve Testosterone - Quick Reference Sheet”; canonical_topic at ER line 8 matches and needs no entity encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “D-Aspartic Acid to Improve Testosterone”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/19/2026”, correctly derived from 2026-0919-0907.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line (ER line 30) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 414-418: what the compound is, the untrained-versus-trained split, the reversal at doubled dose, and the net evidence verdict.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Pituitary/testicular concentration → ER line 414; single positive untrained study → ER line 416; null trained trials and the fall at doubled dose → ER line 416; “near-silent on long-term safety” → ER line 418.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “mirror-image amino acid”, “pituitary gland”, “testicles” and “untrained men” are all lay-readable.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Studies are referred to only as “one small short study” and “later studies”; no names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Directional language only (“a rise”, “found none”, “a fall”); the ER’s 42% figure is not carried over.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items trace to ER lines 245-270, eight from the “Populations who should avoid” list plus the absolute contraindication at ER line 249.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the ER avoid-list; no ER contraindication omitted and none invented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine discrete <li> elements at lines 567-586.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale correctly stripped: “in whom the reproductive axis is still maturing” (ER line 266) and “given the estradiol suppression at higher doses” (ER line 269) are both dropped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds preserved: “above 4.0 ng/mL pending assessment”, “below 45 mL/min/1.73 m²”, “T-score below −2.5”, and the severity class “Moderate-to-severe”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does identify such populations (ER lines 261-270) and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items trace to ER lines 251-259.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Aromatase inhibitors, OTC medicines, testosterone-directed supplements, estrogen-lowering supplements and pre-workout mixtures are carried; antiseizure medications, memantine/ketamine and testosterone replacement are correctly omitted because they already appear under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Five discrete <li> elements at lines 594-607.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER mechanistic rationale and “Mitigation:” clauses stripped; no dash-trailing content remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved in every item; only the Latin binomials for ashwagandha and tongkat ali (ER line 255) are trimmed, with the common names retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight interaction bullets and the section is correspondingly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol lines 292, 300 and 304.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and duration, time of day, and single-versus-split dosing are the three decision-relevant execution parameters; the remaining ER bullets are contextual or population-specific rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; values (“3 g daily × 12 days”, “Morning, empty stomach”, “Single morning dose”) and sub-lines all map to ER text.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Total testosterone at 12 days (ER line 347), sperm motility at 3 months (ER line 157) and the short half-life (ER line 302) are the ER’s three timing facts.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Total testosterone (the review’s primary outcome, ~42% rise) precedes sperm motility (a non-central outcome), with the pharmacokinetic half-life last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time aspects exist in the ER; all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated with ER-traceable content; time_3_sub reproduces ER line 302 almost verbatim.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER line 347), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Both populated tiers map to the ER headings at lines 147, 153, 161 and 165.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544-557.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Tier lines are bare semicolon-separated noun phrases; the ER’s magnitudes (42%, 10.6%→15.2%, P = 0.047) and study attributions are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in either benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high (line 544) and benefits_medium (line 545) are empty with style="display: none", matching the ER’s “No benefit reaches High/Medium” at lines 139 and 143.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six risks map to the ER headings at lines 195, 203, 209, 217, 221 and 225.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 619-634.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Tier lines carry the ER heading text only; the 16% estradiol reduction, the 12.5% testosterone fall and all confidence intervals and P values are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high (line 619) is empty with style="display: none", matching the ER’s “No risk reaches High” at line 191.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence trace to the ER Monitoring Protocol & Defining Success section (ER lines 373-385).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present with matching functional ranges: total testosterone, free testosterone, LH, estradiol, SHBG, hematocrit, PSA, eGFR and ALT.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 774-778 carries the full ER schedule: baseline (two morning fasted draws a week apart), end of the first twelve-day cycle, four weeks, then every twelve weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items trace to the ER qualitative-marker list at lines 389-394.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Complete: morning erections, libido, training recovery and strength, mood/irritability/drive, sleep quality, afternoon energy — all six carried verbatim.

Issues 19/09/2026 09:18

Pass rate 100.00%. No issues found.

Issues 19/09/2026 09:12

1. 12.3 / 12.4 — Benefit parentheticals not stripped: benefits_low (line 549) retains “(conflicted)” and “(not central to testosterone)” and benefits_speculative (line 555) retains “(neither central to testosterone)”, although 12.4 requires all parenthetical content to be stripped.
2. 13.3 / 13.4 — Risk parenthetical not stripped: risks_low (line 622) retains “(conflicted)” after “Reduction in total and free testosterone at six grams daily”, although 13.4 requires parenthetical content to be stripped.
3. 1.3 — Contraindication scope broadened: stop_items line 579 reads “Competitive athletes who cannot verify third-party batch testing”, dropping the ER’s qualifier “under anti-doping jurisdiction” (ER line 270) and widening the contraindication to all competitive athletes.

Fixes 19/09/2026 09:12

1. 12.3 / 12.4 — Benefit parentheticals stripped: Removed “(conflicted)” and “(not central to testosterone)” from benefits_low and “(neither central to testosterone)” from benefits_speculative, leaving only the key facts.
2. 13.3 / 13.4 — Risk parenthetical stripped: Removed “(conflicted)” from the risks_low entry “Reduction in total and free testosterone at six grams daily”.
3. 1.3 — Contraindication scope restored: Changed the athlete contraindication from “Competitive athletes who cannot verify third-party batch testing” to “Competitive athletes under anti-doping jurisdiction who cannot verify third-party batch testing”, matching the ER’s scope.